258 related articles for article (PubMed ID: 28091711)
1. Anticholinergic prescription: are healthcare professionals the real burden?
Araklitis G; Thiagamoorthy G; Hunter J; Rantell A; Robinson D; Cardozo L
Int Urogynecol J; 2017 Aug; 28(8):1249-1256. PubMed ID: 28091711
[TBL] [Abstract][Full Text] [Related]
2. Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder.
Araklitis G; Robinson D; Cardozo L
Clin Interv Aging; 2020; 15():1493-1503. PubMed ID: 32921995
[TBL] [Abstract][Full Text] [Related]
3. [Impact on cognitive function of anticholinergic drugs used for the treatment of overactive bladder in the elderly].
Kerdraon J; Robain G; Jeandel C; Mongiat Artus P; Gamé X; Fatton B; Scheiber-Nogueira MC; Vetel JM; Mares P; Petit AC; Amarenco G;
Prog Urol; 2014 Sep; 24(11):672-81. PubMed ID: 25214448
[TBL] [Abstract][Full Text] [Related]
4. Treatments for overactive bladder: focus on pharmacotherapy.
Geoffrion R;
J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
[TBL] [Abstract][Full Text] [Related]
5. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly.
Scheife R; Takeda M
Clin Ther; 2005 Feb; 27(2):144-53. PubMed ID: 15811477
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist's knowledge regarding the management of overactive bladder in elderly women.
Araklitis G; Rantell A; Baines G; Flint R; Robinson D; Cardozo L
Eur J Obstet Gynecol Reprod Biol; 2021 Mar; 258():269-272. PubMed ID: 33485264
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of providers who prescribed only anticholinergic medications for overactive bladder in 2020.
Carr DN; Macharia A; Hacker MR; Winkelman WD
Am J Obstet Gynecol; 2023 Sep; 229(3):316.e1-316.e7. PubMed ID: 37244459
[TBL] [Abstract][Full Text] [Related]
8. Dementia Associated with Anticholinergic Drugs Used for Overactive Bladder: A Nested Case-Control Study Using the French National Medical-Administrative Database.
Malcher MF; Droupy S; Berr C; Ziad A; Huguet H; Faillie JL; Serrand C; Mura T
J Urol; 2022 Oct; 208(4):863-871. PubMed ID: 35686842
[TBL] [Abstract][Full Text] [Related]
9. AUGS Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
This document was developed by the American Urogynecologic Society (AUGS) Guidelines Committee with the assistance of Tonya N. Thomas, MD, and Mark D. Walters, MD. This document reflects clinical and scientific advances as of the date issued and is subject to change. The information should not be construed as dictating an exclusive course of treatment or procedure to be followed. Its content is not intended to be a substitute for professional medical judgment, diagnosis, or treatment. The ultimate judgment regarding any specific procedure or treatment is to be made by the physician and patient in light of all circumstances presented by the patient.
Female Pelvic Med Reconstr Surg; 2017; 23(3):177-178. PubMed ID: 28441276
[TBL] [Abstract][Full Text] [Related]
10. Anticholinergics for overactive bladder therapy: central nervous system effects.
Chancellor M; Boone T
CNS Neurosci Ther; 2012 Feb; 18(2):167-74. PubMed ID: 22070184
[TBL] [Abstract][Full Text] [Related]
11. Anticholinergic burden in the Japanese elderly population: Use of antimuscarinic medications for overactive bladder patients.
Yoshida M; Kato D; Nishimura T; Van Schyndle J; Uno S; Kimura T
Int J Urol; 2018 Oct; 25(10):855-862. PubMed ID: 30069973
[TBL] [Abstract][Full Text] [Related]
12. The cognitive effect of anticholinergics for patients with overactive bladder.
Welk B; Richardson K; Panicker JN
Nat Rev Urol; 2021 Nov; 18(11):686-700. PubMed ID: 34429535
[TBL] [Abstract][Full Text] [Related]
13. Medication Profiles of Patients with Cognitive Impairment and High Anticholinergic Burden.
Green AR; Reifler LM; Boyd CM; Weffald LA; Bayliss EA
Drugs Aging; 2018 Mar; 35(3):223-232. PubMed ID: 29404965
[TBL] [Abstract][Full Text] [Related]
14. Inequities in Filled Overactive Bladder Medication Prescriptions in the US.
Luchristt D; Bretschneider CE; Kenton K; Simon M; Brown O
JAMA Netw Open; 2023 May; 6(5):e2315074. PubMed ID: 37223899
[TBL] [Abstract][Full Text] [Related]
15. [Cognitive adverse effects of anticholinergic medication for overactive bladder in PD/DLB].
Sakakibara R
Rinsho Shinkeigaku; 2013; 53(11):1389-92. PubMed ID: 24292000
[TBL] [Abstract][Full Text] [Related]
16. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.
Welk B; McArthur E
BJU Int; 2020 Jul; 126(1):183-190. PubMed ID: 32167223
[TBL] [Abstract][Full Text] [Related]
17. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
18. Clinical Consensus Statement: Association of Anticholinergic Medication Use and Cognition in Women With Overactive Bladder.
Female Pelvic Med Reconstr Surg; 2021 Feb; 27(2):69-71. PubMed ID: 33497068
[TBL] [Abstract][Full Text] [Related]
19. Anticholinergic medication use for female overactive bladder in the ambulatory setting in the United States.
Ju R; Garrett J; Wu JM
Int Urogynecol J; 2014 Apr; 25(4):479-84. PubMed ID: 24158462
[TBL] [Abstract][Full Text] [Related]
20. The cognitive safety of antimuscarinics in the treatment of overactive bladder.
Araklitis G; Robinson D
Expert Opin Drug Saf; 2020 Oct; 19(10):1303-1313. PubMed ID: 32857638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
